May 11-14, 2021
Virtual Event
Join YUMAB´s team at this year’s PEGS Boston Virtual to get the latest data on YUMAB’s fully human antibody technology platform and learn more about the company’s potential in fully human antibody engineering.
Don’t miss the panel discussion “Novel and Next-Generation Approaches to COVID-19 Therapeutics” on May 11th at 10 a.m. GMT-4 (4 p.m. GMT+2), including the presentation “Novel Anti-SARS-CoV2 Antibody Therapy with Safety Design for Treatment of Moderate to Severe COVID-19” by YUMAB’s CEO Thomas Schirmann.
Visit YUMAB’s virtual booth at the meeting, interact with the team and dowload infos to learn more about your options!
Let us take you there:
People attending from YUMAB:
David Passmore, PhD
Business Development
Linda Kirchner, PhD
Head of Business & Finances
Alexander Ehm
Head of Global Business Development
Jonas Kügler, PhD
Head of Research & Technologies
Thomas Schirrmann, PhD
Founder & CEO
YUMAB GmbH
Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany
Phone: +49 531 481170-0
Fax: +49-531 481170-17
